Blank Cover Image

Blockade of CD26 Augments the Therapeutic Potential of Marrow Stem Cells in the Liver

フォーマット:
論文(リポジトリ)
責任表示:
Matsuda, Yasunobu ; Wakai, Toshifumi ; Hirose, Yuki ; Sakata, Jun ; Kobayashi, Takashi ; Osawa, Mami ; Fujimaki, Shun ; Kubota, Masayuki
出版情報:
新潟大学医学部保健学科, 2014-03
掲載情報:
新潟大学保健学雑誌 = 新潟大学保健学雑誌
ISSN:
21884617  CiNii Articles  Webcat Plus  JAIRO
著者名:
Matsuda, Yasunobu
Wakai, Toshifumi
Hirose, Yuki
Sakata, Jun
Kobayashi, Takashi
Osawa, Mami
Fujimaki, Shun
Kubota, Masayuki
続きを見る
巻:
11
通号:
1
開始ページ:
39
終了ページ:
49
バージョン:
publisher
概要:
Background & Aims: The therapeutic potential of marrow stem cells for liver disease is currently unclear. The aim of this study was to investigate whether potentiating the chemotaxis ability of stromal cell-derived factor 1 could augmen t the engraftment of marrow stem cells and ameliorate tissue damage. Methods: Female mice reconstructed with β-galactosidase-positive male marrow cells were repeatedly injected with carbon tetrachloride to induce liver cirrhosis. The statuses of stromal cell-derived factor 1 and its inhibitor CD26 were examined by immunohistochemical staining, enzyme-linked immunosorbent assays and colorimetric assays. Recipients were treated with an inhibitory peptide for CD26(Diprotin A)together with granulocyte colony-stimulating factor, and the marrow-derived cells were tracked through the β-galactosidase activity or sex-determining region on the Y chromosome. Results: Stromal cell-derived factor 1 expression and CD26 activity were both significantly increased and marrow-derived hepatocytes were not observed in liver cirrhosis, suggesting that the potential of stem cell homing is impaired by liver damage. Granulocyte colony-stimulating factor only induced a few cell clusters comprising 2-6 marrow-derived hepatocytes at a late stage of liver cirrhosis. In contrast, when animals with liver cirrhosis were treated with Diprotin A after granulocyte colonystimulating factor-induced stem cell mobilization, marrow-derived hepatocytes increased to 2-4% of the total hepatocytes and both the serum albumin and hepatic hydroxyproline contents were ameliorated(p < .05). Conclusions: Maintaining the chemotaxis ability of stromal cell-derived factor 1 may represent an effective strategy for validating stem cell therapy. 続きを見る
本文リンク

類似資料:

1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
 
11
 
12
 

SATO, Yoshinobu, YAMAMOTO, Satoshi, NISHIMURA, Jun, NABATAME, Nobuyuki, TSUNODA, Kazuhiko, WAKAI, Toshifumi, WATANABE, &hellip;

Niigata University School of Medicine

Iinuma, Yasushi, Kubota, Masayuki, Yagi, Minoru, Kawamura, Hiroki, Tsuchida, Masahito, Takahashi, Satoshi, Abo, Toru

Niigata University School of Medicine

Hamamoto, Takuji, Yuhara, Masaki, Miyazaki, Takashi, Fukase, Masayuki, Kondo, Hiroko, Ikawa, Toshiyuki, Ishioka, Jun, &hellip;

新潟大学理学部

KUBOTA, Masayuki

Niigata University School of Medicine

WAKAI, Toshifumi, WATANABE, Hidenobu, SHIRAI, Yoshio, HATAKEYAMA, Katsuyoshi

Niigata University School of Medicine

Kubota, Yosuke, Sakamoto, Makoto, Kobayashi, Koichi, Koga, Yoshio, Tanabe, Yuji

日本実験力学会

Kobayashi, Shun'ichi, Satow, Kazuhide

新潟大学積雪地域災害研究センター

Kobayashi, Tsuyoshi, Yamagishi, Yuki, Sato, Takashi, Ohkawa, Masashi

電気学会東京支部新潟支所

Kawamura, Seiji, Ando, Masaki, Nakamura, Takashi, Tsubono, Kimio, Tanaka, Takahiro, Funaki, Iklkoh, Seto, Naoki, Numata, &hellip;

IOP Publishing